Skip to main content

Advertisement

Table 1 Demographic characteristics and comorbidity status of the Full Cohort at baseline

From: Head to head comparison of the propensity score and the high-dimensional propensity score matching methods

  Low potency n (%) High potency n (%) Absolute standardized differences
  264,947 (100.0) 139,182 (100.0)  
Age, mean (SD)a 65.6 (10.9) 64.5 (11.3) 0.098
Male sex 118,262 (44.6) 74,702 (53.7) 0.181
At least 5 medical outpatient visits 170,234 (64.3) 77,032 (55.4) 0.182
At least 1 hospitalisation 59,591 (22.5) 45,777 (32.9) 0.234
Myocardial infarction 15,056 (5.7) 18,899 (13.6) 0.270
Stroke 7150 (2.7) 5480 (3.9) 0.069
Hypertension 110,508 (41.7) 59,705 (42.9) 0.024
Hypercholesterolemia 88,458 (33.4) 47,005 (33.8) 0.008
Peripheral vascular disease 5446 (2.1) 3338 (2.4) 0.023
Congestive heart failure 11,337 (4.3) 8830 (6.3) 0.092
Coronary artery bypass graft 3589 (1.4) 3189 (2.3) 0.070
Percutaneous coronary intervention 7742 (2.9) 14,089 (10.1) 0.295
Dispensation of loop diuretics 16,612 (6.3) 10,188 (7.3) 0.042
Dispensation of calcium blockers 64,569 (24.4) 32,192 (23.1) 0.029
Dispensation of beta-blockers 77,669 (29.3) 49,147 (35.3) 0.128
Dispensation of angiotensin receptor blockers 35,741 (13.5) 25,325 (18.2) 0.129
Dispensation of angiotensin converting enzyme inhibitors 52,563 (19.8) 36,030 (25.9) 0.144
At least 5 different drugs dispensed 151,395 (57.1) 84,503 (60.7) 0.073
  1. Comorbidity status, drug dispensations and medical utilization rates were assessed in the year prior to the cohort entry date. Absolute standardized differences are defined as the between group difference over the pooled standard deviation of the two groups
  2. aAt the cohort entry date